ONO Pharmaceutical acquired Deciphera Pharmaceutical, Inc. Thanks to Deciphera for developing essential drugs for treatment or rare, important diseases such as GIST and tenosynovial giant cell tumor and thanks for the close interaction with the sarcoma community over the years

New frontiers in exploiting stroma for therapy. FAP directed precision medicine. Phase I of AVA600 showing tolerability, plasmas/tumour PK and clinical proof of concept response in FAP high tumours. Abstract CT188 #AACR2024 The ICR The Royal Marsden NHS Foundation Trust ECMC Network

ASCO has finally launched the new membership model, which provides full access to educational resources, career development plans, multiple journals and discounted access to the Annual Meeting to the members. Join ASCO today! asco.org

SpringWorks applied for EMA approval of nirogacestat for adult desmoid fibromatosis.Believe it or not: at present no drug has EU marketing authorization for this disease, which causes significant morbidity in our patients. Let‘s make off label use of drugs in this setting history

PEComa - to me one of the most enigmatic subtypes of soft tissue sarcoma: development of a new prognostic score discriminating between indolent and malignant variants. Read Gantzer et al. doi.org/10.1002/cncr.3…

🚨Hi #Sarcoma Community

Please follow my brand-new lab account for lab updates, science, backstage pics, and much more!
🧬🎯🧑‍🔬

#Sarcoma #LabResearch #Barcelona #ProudPI

Vall d’Hebron Institute of Oncology (VHIO) ASEICA SEOM The Life Raft Group GEIS Asociación Sarcomas Grupo Asistencial 🎗 Fundación Fero Asociación Española Contra el Cáncer CRIS contra el cáncer

Optical Genome Mapping, a fascinating new diagnostic tool for comprehensive cytogenetic analysis for sarcomas. Read Baelen J et al. doi.org/10.1016/j.jmol…

CONDOR 2024 in Bordeaux: THE meeting for people interested in the sarcoma microenvironment and immunotherapy. Check condorprogram.com/symposium-2nd-…

Vesalius‘ book ‚De humani corporis fabrica' with his personal notes comes back to his alma mater, KU Leuven. What a present for the academic community on the occasion of our 600th birthday next year. Spectacular! nieuws.kuleuven.be/nl/2024/de-hum…

Mark your agenda now:

- FORTRESS 2025 in Essen (Germany) February 13, 14.

- FORTRESS 2026 in Leuven (Belgium)
February 12-14

8 minutes of fame, 2 days of science, 2 nights of fun and networking for every sarcomologist!

FORTRESS 2024 - what a group!

Don‘t know what others think, but for me Guzzi was the ideal choice for our informal pre-FORTRESS get-together. More to come the next evenings!

By invitation only, and full house: FORTRESS 2024

Amazing to see that the local FORTRESS team hardly needs any pressure to proceed with the very last steps of administrative preparation of the Workshop!

Only one week until FORTRESS 2024 starts over here. Program final, many slide decks received, posters printed, hotels filled, social events fully arranged and the whole local team getting ready to rumble.

#NeuesausderForschung
Bluttest sagt Therapieerfolg bei Sarkomen voraus 💙Mehr Infos: udue.de/1524
Uni Duisburg-Essen @unidue.bsky.social Uniklinikum Essen Nature Medicine
#CancerResearch

Slide decks and posters for FORTRESS are FLOODING in, 2 1/2 weeks prior to the Workshop! I always describe the sarcoma community as mega-friendly and non-competitive but didn‘t realize how proactive our people are. My excitement increases exponentially every day now, can‘t wait…

FORTRESS 2024 final program now online! A lot of hard preparatory work went into this, and we are pretty excited about the outcome. This will be such a cool workshop again. kuleuven.be/fortress/progr…

📢We are hiring! #PhDposition at Vall d’Hebron Institute of Oncology (VHIO)

🎯We aim to uncover novel patterns of chromosome instability in #cancer using
💻multi-omic analyses
🧬functional validations
💊to impact in patients

My group▶️vhio.net/pf/sarcoma-tra…
Apply▶️vhio.net/es/vhio-phd-op…

Questions? DM or email!

Just published a comprehensive review on the use of topoisomerase I inhibitors for treatment of sarcoma and their potential application as cytotoxic payload of novel, promising sarcoma-specific antibody/drug conjugates. Read doi.org/10.1159/000535…